Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pan-T booster co-expressing MSLN CAR T cell
- Development stage
- Phase 2
- Lead developer
- UTC Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
The Pan-T booster co-expressing MSLN CAR T cell is a novel chimeric antigen receptor (CAR) T-cell therapy designed to target mesothelin (MSLN), a tumor-associated antigen highly expressed in various solid tumors. This investigational therapy involves engineering patient-derived T cells to express a synthetic receptor that recognizes and binds to mesothelin on the surface of cancer cells, enabling targeted immune-mediated destruction of these cells. The "Pan-T booster" system refers to enhancements intended to improve the proliferation, persistence, and anti-tumor activity of the modified T cells. The primary indication for this therapy is advanced or metastatic solid tumors expressing mesothelin[1][2][4]. Clinical trials are ongoing to evaluate its safety and efficacy.
- Other names
- Pan-T Booster Co-expressing Mesothelin CAR T CellPan-T Booster MSLN CAR T cell therapy
02
Targets
Mesothelin
Beyond the preview
Go deeper on Pan-T booster co-expressing MSLN CAR T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pan-T booster co-expressing MSLN CAR T cell.